Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Jeffrey Fasy joins Discovery Health Partners as Chief Financial Officer


Jeffrey Fasy, Discovery Health Partners CFO

“Jeff will be strong leader and help us navigate toward our overall key results.”

Discovery Health Partners has tapped Jeffrey Fasy as its new Chief Financial Officer. Fasy brings decades of strategic financial management and financial analytics capabilities, along with robust experience in healthcare technology and data-centric organizations.

“We are pleased to add Jeff to our executive team,“ said Discovery CEO Jason Brown. “His skill set combines growth management expertise and deep appreciation for delivering continued client value. Jeff will be strong leader and help us navigate toward our overall key results.”

“I’m thrilled to have landed at Discovery,” commented Fasy. “We have great people and a very strong foundation to build on. I’m looking forward to helping the team sharpen their focus on client value, which I believe is the way we all win—our clients, employees, investors, and Discovery.”

Fasy most recently served as SVP, Financial Planning and Analysis, for nThrive, a revenue cycle management company for health care providers, and as Vice President of Revenue Assurance and Global Financial Planning and Analysis for Cotiviti, a solutions and analytics company for healthcare companies. Prior to those, Fasy held a variety of financial leadership roles at companies such as Equifax, SNF Holding Company, Kemira Chemicals, UCB, Inc., and Procter & Gamble.

Fasy’s appointment follows other recent significant growth news coming out of Discovery, including its recent acquisition of Consova and its seventh consecutive placement on the Inc. 5000 list of fastest growing companies in America.

About Discovery Health Partners

Discovery Health Partners’ mission is to deliver unique, actionable analytic insights and technology-powered solutions to help healthcare payers improve payment integrity, increase revenue optimization, and maximize efficiencies. Serving more than 80 health plans across the U.S., including nine of the 10 largest U.S. health plans, Discovery has been recognized consistently for its growth and innovation—earning a spot on the Inc. 5000 list seven years in a row, the Crain’s Fast 50 four times, and a prestigious FutureEdge 50 Award from IDG for innovations in machine learning. For more information on Discovery Health Partners, go to http://www.DiscoveryHealthPartners.com.

Share article on social media or email:

PlatformQ Health to Host the GBS|CIDP Foundation’s 2020 Virtual Summit


“Registration has been at an all-time high with over 1,300 registrants reserving their ‘seat’ so far. Having an inclusive virtual solution that makes it easy for people to attend the event from the comfort of their own homes… has always been important for the rare community but is critical now.”

PlatformQ Health is excited to leverage their Conduit Platform, a leading omnichannel event and digital engagement solution, to help the GBS|CIDP Foundation present their very first Virtual Summit next month. The 2020 Virtual Summit takes place on October 3rd from 10am-2pm and will feature 13 sessions and 10 speakers as well as live chat sessions between attendees, faculty and foundation.

Traditionally, this summit is held online, but due to travel and gathering restrictions, an online solution was necessary this year. The GBS/CIDP Foundation selected PlatformQ Health’s recently launched Conduit Platform to host their patient summit online, allowing them to easily host an engaging, interactive, virtual event that will make it easy for participants to watch insightful presentations, engage with wellness and medical experts and make connections with other attendees. The free virtual summit will feature live programming from What’s New in Research, Treatments and Clinical Trials, Commonly Asked Questions for GBS, CIDP and Variants to Tools for Managing Stress, Youth & Teens with GBS|CIDP and Yoga from Your Chair. Speakers for the program include leading researchers, clinicians, advocacy and foundation heads, academics, and wellness experts. PlatformQ Health is also a proud sponsor of this 2020 Virtual Summit alongside Accredo Specialty Pharmacy, Argenx, CSL Behring, Grifols, Takeda, UCB, and KORU Medical Systems.

PlatformQ has been a pioneer in the field of live, video-based education for more than 10 years. Robert Rosenbloom, CEO of PlatformQ Health shares, “During this time, we have learned that the success of virtual education and online events requires both the underlying technology that provides an engaging, interactive experience for attendees, as well as a team of seasoned program and production experts to support the online event itself. We are excited to support the GBS|CIDP Foundation as a partner and national sponsor, with an interactive solution that will enable this large-scale online event to include live video streaming, live chat, a welcoming user experience, insight tracking, and a flexible environment for on-demand viewing after the event.”

“Our ongoing partnership with PlatformQ Health has helped us create valuable digital education for families affected by GBS and CIDP. We were pleased to learn they could also help us transform our 2020 summit into an online global event. Registration has been at an all-time high with over 1,300 registrants reserving their ‘seat’ so far, significantly more than would normally be able to attend an in-person event. Having an inclusive virtual solution that makes it easy for people to attend the event from the comfort of their own homes, without having to travel has always been important for the rare community, but is critical now,” says Lisa Buter, Executive Director of the GBS|CIDP Foundation.

A Partnership Committed to Supporting Patients and Caregivers with Trustworthy Digital Education

Over the years, PlatformQ Health and the GBS|CIDP Foundation have collaborated to produce virtual patient/caregiver education and accredited HCP activities to help clinicians and families understand conditions, communicate more effectively, and empower patients and caregivers to become more active participants in their care.

Recently, the pair collaborated to produce, “Learn About Multifocal Motor Neuropathy (MMN) and Take Action: An Education Program for Patients and Families,” a 3-part virtual patient education program that is now available to watch on-demand on NeuroCareLive.com. During this program, patients with MMN and their caregivers learn about the condition, its treatments and what they can do to continue performing their daily tasks.

Other recent online programs include “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Addressing Diagnostic and Treatment Challenges” and “Treatment Options for CIDP: Information for People Living with CIDP and Their Caregivers.” CME collaborations have garnered attention at major medical conferences like the American Academy of Neurology (AAN) Annual Meeting. The e-poster and session with panelists discussing the impact of the education can be found here.

Later this year, the pair will also be continuing their partnership to produce their October 29th patient-caregiver focused activity, “How Can Participating in a Clinical Trial Help Me? A Focus on CIDP and Related Disorders.” This innovative program will help address some of the fundamental educational and operational challenges getting patients to enroll in clinical trials in rare diseases. Industry sponsors will also be given opportunity present online directly to patients and caregivers their specific trials in CIDP.

About the GBS|CIDP Foundation

The GBS | CIDP Foundation International is a global nonprofit organization supporting individuals and their families affected by Guillain-Barre’ syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and related conditions through a commitment to support, education, research and advocacy. We support patients by nurturing a global network of volunteers, healthcare professionals, researchers and industry partners to provide them with critical, timely, and accurate information; We educate doctors, clinicians, patients and caregivers to increase awareness and understanding; We fund research through grants, establishing fellowships and other appropriate avenues to identify the causes of and discover treatments; We advocate at the federal, state, and grassroots levels to educate policymakers and help them make informed decisions that benefit our patient community.

About PlatformQ Health

PlatformQ Health Education is the leading provider of interactive digital medical education for clinicians, patients, and caregivers. To improve patient care, PlatformQ Health Education creates video-first educational modules with premier partners, so learners can better understand conditions, available treatment options, and the latest research. The company’s proprietary platform allows participants to engage in real-time discussion with scientific, research and patient care experts – and the integrated learning solution enables advocates, administrators, health systems and plans, foundations, societies, member organizations and associations to measure the impact of their education.

Share article on social media or email:

NeuroFlow Expands Partnership with U.S. Air Force, Wins $1.5M Contract to Increase Mental Health Care Access


NeuroFlow, the leader of digitally enabled behavioral health integration, has secured a contract with the United States Air Force to expand its platform to multiple sites, enhancing and scaling care delivered by administrators and medical personnel.

The partnership spans across multiple major commands empowering Airmen to manage their own mental health and build resilience for peak performance. The technology will help administrators monitor the ‘combat readiness’ of Airmen, forming positive routines and creating a streamlined process for identifying at-risk individuals and adjusting treatment plans in real-time.

“Serving our Nation’s Armed Forces is an immense honor. We understand the challenges faced by military populations when treating and managing mental health symptoms,” said NeuroFlow CEO and former Army Captain Chris Molaro. “It’s our objective to leverage technology in a way that allows everyone to take control of their own health, and we look forward to expanding our work with the U.S. Air Force on this critical mission.”

NeuroFlow began working with AFWERX, a United States Air Force program with the goal of fostering a culture of innovation within the service, in late 2019 after being awarded an initial trial contract. After integrating and validating the behavioral health platform on-site at Peterson Air Force Base with AFMS clinical specialists, NeuroFlow successfully won its bid on a more extensive contract to scale the technology.

A heightened awareness around the topic of mental health has prompted leadership to seek out technology-driven solutions focused on wellness and resiliency. “This partnership reinforces our commitment to finding innovative ways to ensure not just the combat readiness of our Airmen but their overall quality of life,” said Major Judy Cole, 21st Medical Group Mental Health Flight commander.

In the coming weeks, NeuroFlow’s technology will be deployed within a division of the U.S. Space Force, laying the groundwork for an integrated approach to physical and mental health care. The integrity of the platform ensures individual privacy and relies on user-generated data to make informed decisions about care. Within the scope of work, NeuroFlow will also assess the technology’s long-term ability to lower medical costs and increase combat readiness.

About NeuroFlow

NeuroFlow is a digital health company combining workflow automation, consumer engagement solutions, and applied AI to promote behavioral health integration in all care settings. NeuroFlow’s suite of HIPAA-compliant, cloud-based tools simplify remote patient monitoring, enable risk stratification, and facilitate collaborative care. With NeuroFlow, health care organizations can finally bridge the gap between mental and physical health in order to improve outcomes and reduce the cost of care. http://www.neuroflow.com.

About AFWERX

Established in 2017 by the Secretary of the Air Force and reporting to the Vice Chief of Staff of the Air Force, AFWERX is a catalyst for agile Air Force engagement across industry, academia and non-traditional contributors to create transformative opportunities and foster an Air Force culture of innovation. The ultimate aim is to solve problems and enhance the effectiveness of the Air Force. AFWERX enables thoughtful, deliberate, ground-up innovation across the Air Force. They do this through an innovation approach that combines startup urgency with the largest pool of motivated talent in the world to uncover opportunities to improve Air Force capabilities, connect and engage the right stakeholders, and facilitate outcomes.

Share article on social media or email:

Lumicell Announces Initiation of NIH/NCI Academic-Industry Study of its LUM Imaging System


Lumicell logo

Lumicell logo

“We’re encouraged by the data shown in the Phase C trial – and this next study supplements the ongoing pivotal study as an important piece in improving patient care and furthering innovations in breast cancer treatment.”

Lumicell, Inc. today announced that Dr. Barbara Smith, Director of the Breast Program at Massachusetts General Hospital, has begun a multi-phase, randomized clinical study utilizing the LUM Imaging System to obtain additional safety and efficacy data in breast cancer supported by an R01 award from the National Cancer Institute. The study follows compelling results from a multi-center Feasibility Phase C trial and runs concurrently with Lumicell’s pivotal trial. The study, led by Barbara Smith, is a collaboration with investigators Dr. Shelley Hwang at Duke, Dr. Irene Wapnir at Stanford, Dr. Anees Chagpar at Yale, and Dr. Kelly Hunt at MD Anderson and with Lumicell.

This new NCI academic-industry clinical study will enroll approximately 400 patients, including an arm consisting of patients receiving neoadjuvant therapy. The study also focuses on collecting data as the first step to investigate the potential long-term impact of the LUM Imaging System in breast cancer treatment.

“Over the last decade, neoadjuvant therapies have become more prevalent as a standard treatment for breast-conserving surgeries. While there have been studies on the effectiveness of neoadjuvant therapies alone, we’re eager to study long-term outcomes of patients who also have the benefit of using in-vivo imaging to find residual cancer,” said Dr. Smith. “We’re encouraged by the data shown in the Phase C trial – and this next study supplements the ongoing pivotal study as an important piece in improving patient care and furthering innovations in breast cancer treatment.”

The LUM Imaging System was developed to enable surgeons to see and remove residual cancer in real time during the initial surgery. It is designed to reduce the risk of second surgeries and cancer recurrence while minimizing healthy tissue removal. This new study follows compelling clinical results from Lumicell’s 234-patient, 16-site Feasibility Phase C study that demonstrated the detection and removal of residual cancer, for both invasive cancers and ductal carcinoma in situ (DCIS), in 11% of patients after standard of care lumpectomy. Data from the Phase C study and the ongoing pivotal study will be used to support an application to the FDA for market approval for the LUM Imaging System.

“We are very excited to collaborate with Dr. Smith and this prestigious group of investigators on this important trial and look forward to evaluating the potential for improved treatment in breast cancer care by using the LUM Imaging System,” said Kevin Hershberger, CEO of Lumicell. “Our focus in developing the Lumicell System has been to improve patient outcomes by guiding the removal of residual cancer during initial surgeries and we are thrilled to extend this to patients receiving neoadjuvant therapies.”

For more information about Lumicell’s clinical trials, visit http://www.lumicell.com/clinical-trials/clinical-trials.php.

About Lumicell, Inc.

Lumicell is a technology leader in the field of image-guided cancer surgery. The company has developed a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The company’s LUM Imaging System has unprecedented ability to see and remove cancer cells remaining in the surgical cavity – beyond the margin of the specimen – and has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the LUM Imaging System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal, ovarian, peritoneal and brain cancers. Additional future indications are planned to include surgeries for lung, pancreatic, and other solid tumor cancers. For more information, please visit http://www.lumicell.com.

Share article on social media or email:

San Antonio-based software company is changing the face of the clinical trial industry


Our system is about efficiency and streamlined processes that essentially remove the need for on-site data verification and outdated paper data collection.

In a world becoming more and more virtual, sites, sponsors and CROs are scrambling to find solutions that allow clinical trials to continue uninterrupted. One San Antonio-based software company is proving that they can do just that.

“RealTime DecenTRIAL is an innovative solution that will ultimately change the way the clinical trial industry does business,” says RealTime Software Solutions CEO, Rick Greenfield. “The system streamlines operations by offering an all-in-one solution that provides sites, sponsors, and CROs access to needed clinical trial documents and data remotely while improving site efficiency, lowering trial costs and improving quality and patient safety.”

The clinical trial industry has relied heavily on paper to collect critical trial data leaving room for error and adding high overhead costs to both the sites and sponsors.

“Many sites are still using paper systems, and even those are using electronic paperless systems are still having to transcribe source data into EDC systems,” says Greenfield. “This means that sites are doing more work and the sponsor has to verify all source data either on-site or remotely and in-turn, pay for electronic data capture (EDC) systems. This process comes at a high cost for sponsors, which would be eliminated by utilizing our DecenTRIAL system.”

Though many sites and sponsors alike have been slow to adopt new systems, the coronavirus has forced the industry to look at electronic systems in a new light. Experts say that the change will only help to accelerate the clinical trial process.

Benefits to the DecenTRIAL system include greater efficiency in all phases of the trial process for both sites and sponsors, real-time data delivery, instant data review from any location, and substantial cost savings. This includes access to source and regulatory documents through a virtual monitoring portal and built-in query access. The system is also GDPR, HIPAA and Part 11 compliant with complete audit trails and data controls.

“It’s not just about saving money by eliminating the need for EDC,” says Greenfield. “Our system is about efficiency and streamlined processes that essentially remove the need for on-site data verification and outdated paper data collection.”

To learn more about RealTime-DecenTRIAL, visit RealTime-CTMS.COM or call 210-852-4310.

About RealTime-CTMS

RealTime Software Solutions, LLC is a leader in cloud-based software solutions for the clinical research industry and is dedicated to solving problems and providing systems that make the research process more efficient and more profitable. We are constantly listening to our customers and to the needs of the industry to provide new innovations that streamline processes and help us all achieve our operational goals. RealTime’s focus on exceptional customer service ensures that all clients get the most out their RealTime solutions.

Share article on social media or email:

Contagion Control Solutions Names Karen Lucchesi CEO


Contagion Control Solutions announced today that Karen Lucchesi is now the company’s new CEO. The company also announced its new ULV Mist Cold Fogger technology to spray a non-toxic, EPA-approved solution via micron-sized particles to disinfect and sanitize surfaces quickly. Using hypochlorous acid (HOCL), the company’s solutions are non-toxic, safe, eco-friendly, and effective at rapidly disinfecting and drying surfaces (within 25 feet of the ULV Cold Mist Fogger) which are accessible to large groups of people. The company helps property owners and managers simultaneously save money and time and minimize health risks to their employees, patients, customers, residents, and others safe from viruses and bacteria.

Karen Lucchesi said, “Based on our backgrounds in alternative medicine, we recognized a need for safe, effective, cost-effective and robust sanitizing option for our customers. The challenge was to find an option that was not toxic to humans or animals for all forms of properties such as nursing homes, schools, airplanes, trains, leasing offices, franchise locations, and buildings where large numbers of people will be present in a short period. Our company decided on using a Hypochlorous acid (HOCL)-based solution, which is FDA approved, EPA-approved, safe for use around people’s eyes, sanitizes with just one application, and is non-toxic.”

Lucchesi indicated that her concern about commercial sanitizers was confirmed recently where she and her colleagues noticed airlines using spraying and fogging solutions that are toxic to humans and, simultaneously, likely to have caused damage plastics and other aircraft interiors materials. She believes that such sanitizing solutions and sprays, in order to meet new health mandates, actually can harm both individuals’ health as well as corporations’ profits alike; and that is why the company decided to pursue safe, cost-effective options to meet the needs of both customers and companies’ profits.

The company also announced its focus on stadiums, arenas and other public venues. Citing her background in working in professional baseball (Karen is the daughter of former MLB manager Frank Lucchesi), Lucchesi expressed her intent to help athletes, team staff and reporters to be safe during this era of Coronavirus and COVID-19. One of the company’s products includes a piece of equipment, akin to an airport screening area, where athletes can walk through and be sprayed with the non-toxic sanitizing fog solution. This way athletes and their equipment can be safely and quickly sanitized before and after they are on the playing field or court.

Company officials also indicated that they are working closely with school districts to help with “fogging” (sanitizing with the non-toxic nanoparticles) buses quickly and efficiently. The goal is to make it easier for bus drivers and bus maintenance staff to not have to spend inordinate amounts of time, and risk of injury, manually wiping down the interiors of buses. Continuing its work with school districts, the company also is offering solutions to improve student and staff safety with equipment for fogging gyms, classrooms and other educational building areas.

Lucchesi indicated that HOCL-based sanitizers benefit all relevant parties because the chemical is naturally-occurring in the human body, destroys some pathogens in less than a minute, meets OSHA Bloodborne pathogen guidelines, and meets AOAC efficacy testing requirements for hospital disinfection. She said that the ULV Cold Mist Fogger breaks the HOCL solution into nanoparticles and sprays the “fog” onto surfaces and in the air where most transmission occurs. The mist then disinfects the surfaces and dries within seconds. The company also has other disinfection mechanisms such as multi-function disinfecting robots and walkthrough gates/screening instruments, including temperature checks, safety kits, hand soap/sanitizer dispensers, and more.

Company officials emphasized the use of its EPA and FDA approved chemicals to help those who are deemed to be vulnerable populations such as elderly in nursing homes and assisted living facilities. While the current emphasis is on sanitizing to remove the risks of Coronavirus and COVID-19, company officials emphasized that its non-toxic solutions will sanitize other health concerns such as MRSA – all done without toxic chemicals frequently found to be used in current building and public transportation sanitizing efforts. The company also indicated that its HOCL-based product line quickly addresses sanitizing and disinfecting needs for over 30 kinds of viruses and bacteria, some as quickly as 15 seconds, and those are addressed in detail on the company’s Clinical Information page:

https://contagioncontrolsolutions.com/clinical-information

Here is the link from the EPA website approving Hypochlorous Acid (HOCL): https://www.epa.gov/newsreleases/epa-takes-action-assure-availability-disinfectant-products-use-against-novel

Interested parties may discover more about Contagion Control Solutions through its website. Media inquiries may contact Karen Lucchesi at the information contained at the bottom of this release.

Share article on social media or email:

NeoTract Designates Dr. Arman Cicic as UroLift® Center of Excellence


News Image

“We are proud to name Dr. Arman Cicic as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Arman Cicic, D.O., Metropolitan Urology Group in Racine, WI, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Cicic has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Arman Cicic as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Are You Paying Too Much for Your Medicare Health and Drug Plans? Find a Better Plan with These Tips from The Senior Citizens League


Mary Johnson
Social Security and Medicare Policy Analyst
The Senior Citizens League (TSCL)

“Unless you match your needs to the lowest costing plan that specifically cover the drugs you take, you could be needlessly spending hundreds of dollars too much for your coverage,” says Mary Johnson, a Medicare policy analyst for The Senior Citizens League.

Chances are high that most retirees are paying too much for their Medicare health and drug plans, says The Senior Citizens League (TSCL). “Unless you match your needs to the lowest costing plan that specifically cover the drugs you take, or Medicare Advantage plan that includes the doctors and hospitals that you typically use in its network, you could be needlessly spending hundreds of dollars too much for your coverage,” says Mary Johnson, a Medicare policy analyst for The Senior Citizens League. “For married couples, this can mean different health or drug plans for each of you,” she notes. Yet surveys conducted by senior advocates, including The Senior Citizens League, indicate that only a small portion of Medicare beneficiaries ever shop around for better coverage at the lowest cost.

Prescription drug costs are the fastest growing expenditure that most people face in retirement, according to research by The Senior Citizens League. “Most retirees have other options that they don’t even know about,” Johnson says. Medicare’s fall Open Enrollment period, which starts October 15th and runs through December 7th, is the time to learn about those other options, and to make changes to health and drug plan coverage.

“Drug and health plans change every year, and so does our health,” Johnson notes. Since 2005, Johnson has volunteered as a Medicare counselor in her underserved area to help neighbors, friends and family navigate through dozens of choices, and to get matched up to optimal health and drug plans. “It’s not uncommon to save hundreds of dollars in a single year,” she says.

In 2019, out-of-pocket costs for prescription drugs averaged more than $3,875 for the year, and that cost is growing by double digits. According to research by Johnson, out-of-pocket prescription drugs costs have increased 252 percent (about 12.6 percent per year) since 2000. “Nobody should be complacent and swallow that kind of increase” Johnson says. “This is not as difficult as it may seem,” Johnson says. “There are people like me ready to help.” Here are a few tips from Johnson on how to find better coverage:

— Make it easy. Get free unbiased help. The consequences of making the wrong choice can be very expensive, but virtually every area of the country has trained Medicare benefit counselors who work through State Health Insurance Assistance Programs (SHIP). Many of these programs operate through local agencies on aging. You can find contact information for a SHIP program in your area at: https://www.shiptacenter.org. Call early and make an appointment. Counseling can be safely done over the phone.

— Use the http://www.Medicare.gov drug and health plan finder tool. Be careful what you Google. Just entering “Medicare drug plans” can pull up a mares’ nest of web sites peddling plans, but what you want is complete information for the county where you live. Rather than bog yourself down trying to compare plans on two or three different sites, stick to http://www.Medicare.gov. All the drug and Medicare Advantage plans serving your county will be listed. You can select your choice by the drugs, and healthcare providers that you use. If you decide to switch from your current plan, it is important to double-check the information listed on Medicare.gov first, and to switch using Medicare’s enrollment tools. That will ensure that your enrollment information goes to the plan of your choice, and that your former plan is automatically notified of your disenrollment.

— Search by the drugs you take and include drugs you only use occasionally. If you have not already got one, make a complete list of the drugs you currently take. Do not try this from memory; read labels, because spelling is important. Check the dosage and quantity that you take daily and monthly. A 90 – day supply is often less expensive per dose than a 30 – day supply, so consider getting your refills that way — especially for generics. Drug prices can vary considerably. The difference in price, particularly for brand name drugs, can be in the hundreds, or even thousands, of dollars.

— Look for plans that provide coverage before the deductible. The standard deductible for drug coverage in 2021 is $445. That is a lot, when the average monthly Social Security benefit is just $1,500. But you might be able to save that much or even more if you are willing to go for the plan with the lowest costing premiums and out-of-pocket costs based on the drugs you actually take. In addition, many plans offer low or zero co-pays for preferred generics “before the deductible,” meaning you will only have to pay for brand and non-preferred generics during the deductible phase of coverage.

— Compare the least expensive way to fill prescriptions, especially comparing the difference between different retail pharmacies and mail order. It makes absolutely no sense, but even drug plans offered by the same insurer vary significantly in drug costs. Often, the difference between plans offered by the same insurer depends on the pharmacy where you fill your prescription (such as CVS vs. Walmart or Walgreens) or retail pharmacy vs. mail order. One job when comparing plans is finding the best places to purchase your prescriptions, and that can vary by the prescription. For example, you may take several common generics that you may be able to fill at zero co-pay by mail, but there is likely to be a small co-pay at retail pharmacies. You may have one or more brand name drugs that would be less costly from a retail pharmacy than by mail (or vice versa). When you have narrowed down your drug plan search, take your drug list that you made when you started, and make notes of whether the best price of the drug will be by mail order, or list the specific retail pharmacy and the estimated co-pay. If you do switch plans, you may need to ask your doctor to call in your prescription to a different pharmacy.

— If diabetic, look for new Medicare drug plans that offer a maximum $35 copay for insulin. Some 2021 drug and Medicare Advantage plans across the country may offer different types of insulin at a maximum co-pay of $35 per month in 2021. This includes all stages of coverage, including the deductible, initial coverage, and the coverage gap. This coverage is only offered to people who do not otherwise qualify for Medicare Part D low-income subsidy or “Extra Help,” and may not be available in all areas of the country. But check.

— If two plans are similar in costs check the general co-insurance for non- preferred generics, brand, and specialty drugs, even if you do not currently take any. Take the plan with the lowest costing non-preferred cost sharing.

To learn more about The Senior Citizens League visit http://www.SeniorsLeague.org.

###

With 1.2 million supporters, The Senior Citizens League is one of the nation’s largest nonpartisan seniors’ groups. Its mission is to promote and assist members and supporters, to educate and alert senior citizens about their rights and freedoms as U.S. Citizens, and to protect and defend the benefits senior citizens have earned and paid for. The Senior Citizens League is a proud affiliate of The Retired Enlisted Association. Visit http://www.SeniorsLeague.org for more information.

Share article on social media or email:

California Casualty’s 2020 Work Hard/Play Hard $5,000 STIHL® Tools Giveaway Ends Oct. 31


Saw Blade with Sun Rising

California Casualty’s 2020 Work Hard/Play Hard Giveaway

California Casualty remains committed to the dedicated professionals who serve our communities.

California Casualty’s 2020 Work Hard/Play Hard $5,000 STIHL® tools giveaway will come to a close October 31st. Interested law enforcement officers, firefighters and EMTs must enter to win at http://www.contest4heroes.com before it’s too late.

Now more than ever, our nation’s public safety professionals are feeling the pressure of their jobs. California Casualty, the auto and home insurance company trusted by these American heroes, offers its annual Work Hard/Play Hard contest as a way to thank them for their role in our communities.

Working to ensure public safety, enforce laws, arrive first to emergencies, and provide reassurance to anxious communities, first responders face challenges and stressors every day.

As a partner to public safety groups across the nation for half a century, California Casualty has witnessed the spirit that drives their sense of duty and appreciates the daily sacrifices they make.

“California Casualty remains committed to the dedicated professionals who serve our communities. We owe them this thank you for all that they do.” said Sr. Vice President Mike McCormick.

Previous Work Hard/Play Hard sweepstakes from California Casualty have awarded public safety personnel with:

  • Liberty Safes,
  • DeWalt Tools,
  • Motorcycles, and
  • Cash

Past winners include an Oregon Police officer; a Colorado Sheriff’s captain; firefighters from California, Nebraska, Ohio and Pennsylvania; and a California Highway Patrolman.

California Casualty will provide one lucky winner $5,000 towards the STIHL® tools of their choice. Entries are being accepted now through October 31, 2020 at http://www.contest4heroes.com. The winner will be announced in November.

Founded in 1914 and headquartered in San Mateo, California with Service Centers in Arizona, Colorado and Kansas, California Casualty provides auto and home insurance to educators, firefighters, law enforcement and nurses across the country. Learn more about California Casualty at http://www.calcas.com or call 1.800.800.9410.

*STIHL® does not a endorse or sponsor this promotion

Share article on social media or email:

ProAct Safety’s Founder Compares and Contrasts BBS and HOP; Recording now available from the RASP Live Networking Event


BBS -vs- HOP: Either, Neither…or Both?

The feedback we have had from attendees has been incredibly positive and I am looking forward to having Terry share more of his wisdom, insight and experience

ProAct Safety, a recognized pioneer of safety excellence strategies, announced its founder and CEO, Terry L. Mathis, lead the live networking event discussion around BBS and HOP, answering many attendee questions. The live event held on August 26th was recorded and is now available on demand at https://www.youtube.com/watch?v=h_9FY3_Hm8o.

Mathis’ session, “BBS vs. HOP: Either, Neither…or Both?,” details the similarities and differences between the two programs and helps attendees determine which will work best for their specific culture.

“Having Terry as our special guest to discuss BBS-vs-HOP brought a fresh and practical perspective from an exceptionally talented and gifted orator. The feedback we have had from attendees has been incredibly positive and I am looking forward to having Terry share more of his wisdom, insight and experience in this very popular and often misunderstood subject,” said Sonni Gopal, RedRisks.com.

For more information about ProAct Safety events, visit http://proactsafety.com/events.

ABOUT TERRY L. MATHIS

Mathis, ProAct Safety’s founder and CEO, is known for dynamic presentations, work and writing in the fields of behavioral and cultural safety, leadership, and operational performance. He is a regular speaker at ASSE and NSC, as well as company and industry conferences. He has been a frequent contributor to industry magazines for more than 15 years and is coauthor of five books, including bestsellers STEPS to Safety Culture Excellence (WILEY, 2013) and Forecasting Tomorrow: The Future of Safety Excellence (SCE Press, 2015). Terry has been listed four consecutive times as one of ‘The 50 People Who Most Influenced EHS’ by EHS Today. Learn more about him at http://www.TerryLMathis.com.

ABOUT PROACT SAFETY

ProAct Safety is a global safety excellence consultancy. The company has completed more than 2,000 successful safety strategy, leadership, culture and behavior-based safety projects in nearly every major industry worldwide. Learn more at http://www.ProActSafety.com.

ABOUT REDRISKS.COM

Founded mid-2019 by Sonni Gopal, Redrisks.com has rapidly grown as a digital platform for risk and safety professionals. Offering a plethora of technical resources and live events with world class leaders, Redrisks.Com is highly respected and well recognized within the risk and safety community. Learn more at https://www.redrisks.com.

Share article on social media or email: